The 9/30/23 launch date in the US market is 2 months later than MYL’s launch date (#msg-142251299), 3 months later than Samsung’s launch date (#msg-139804103), and 8 months later than AMGN’s launch date (#msg-134976468).
I.e. AMGN, the first company to settle with ABBV, got a 6-month head start in the US market relative to all other Humira biosimilars; the settlements from the second to the fourth (and presumably additional ones to come) have US launch spaced 1 month apart, so there’s a tangible disincentive to the settling companies for waiting.
MNTA has not yet settled with ABBV.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”